Literature DB >> 14527904

Adenoma recurrences after resection of colorectal carcinoma: results from the Southwest Oncology Group 9041 calcium chemoprevention pilot study.

David Z J Chu1, Kari Chansky, David S Alberts, Frank L Meyskens, Cecilia M Fenoglio-Preiser, Saul E Rivkin, Glenn M Mills, Jeffrey K Giguere, Gary E Goodman, James L Abbruzzese, Scott M Lippman.   

Abstract

BACKGROUND: Colorectal adenomas are the usual precursors to carcinoma in sporadic and hereditary colorectal cancers (CRC).
METHODS: A total of 220 CRC patients (stages 0, I, and II) were randomized prospectively in a double-blind pilot study of calcium chemoprevention by using recurrent colorectal adenomas as a surrogate end point. This trial is still in progress, and we report the preliminary findings on adenoma recurrence rates.
RESULTS: Synchronous adenomas were present in 60% of patients, and cancer confined in a polyp was present in 23% of patients. The overall cumulative adenoma recurrence rate was 31% (19% in the first year, 29% for 2 years, and 35% for 3 years). The recurrence rates were greater for patients with synchronous adenomas: 38% at 3 years (P =.01). Lower stage was associated with higher adenoma recurrence rates (P =.04). Factors including age, sex, site of primary cancer, and whether the cancer was confined to a polyp were not significantly associated with differences in adenoma recurrence rates.
CONCLUSIONS: The substantial adenoma recurrence rate in patients resected of CRC justifies colonoscopic surveillance on a periodic basis. Patients with higher rates of adenoma recurrences, such as CRC with synchronous adenomas, are ideal subjects for chemoprevention trials.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14527904     DOI: 10.1245/aso.2003.03.037

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  7 in total

Review 1.  Nuclear factor-erythroid 2-related factor 2 as a chemopreventive target in colorectal cancer.

Authors:  Constance Lay Lay Saw; Ah-Ng Tony Kong
Journal:  Expert Opin Ther Targets       Date:  2011-01-25       Impact factor: 6.902

2.  Estimating the unknown parameters of the natural history of metachronous colorectal cancer using discrete-event simulation.

Authors:  Fatih Safa Erenay; Oguzhan Alagoz; Ritesh Banerjee; Robert R Cima
Journal:  Med Decis Making       Date:  2011-01-06       Impact factor: 2.583

3.  Colorectal Chemoprevention Pilot Study (SWOG-9041), randomized and placebo controlled: the importance of multiple luminal lesions.

Authors:  David Z J Chu; Michael A Hussey; David S Alberts; Frank L Meyskens; Cecilia M Fenoglio-Preiser; Saul E Rivkin; Glenn M Mills; Jeffrey K Giguere; Charles D Blanke; Gary E Goodman
Journal:  Clin Colorectal Cancer       Date:  2011-07-22       Impact factor: 4.481

Review 4.  Calcium supplementation for the prevention of colorectal adenomas: A systematic review and meta-analysis of randomized controlled trials.

Authors:  Stefanos Bonovas; Gionata Fiorino; Theodore Lytras; Alberto Malesci; Silvio Danese
Journal:  World J Gastroenterol       Date:  2016-05-14       Impact factor: 5.742

5.  Risk of second primary colorectal cancer among colorectal cancer cases: a population-based analysis.

Authors:  Kavitha P Raj; Thomas H Taylor; Charlie Wray; Michael J Stamos; Jason A Zell
Journal:  J Carcinog       Date:  2011-03-17

6.  Risk factors for metachronous adenoma in the residual colon of patients undergoing curative surgery for colorectal cancer.

Authors:  Abhilasha Patel; Nigel Williams; Nicholas Parsons; Omar Ali; Francesca Peters; Reesha Ranat; Jasmine Shah; Emma Spector; Ramesh P Arasaradnam
Journal:  Int J Colorectal Dis       Date:  2017-08-21       Impact factor: 2.571

Review 7.  Chemoprevention of colorectal cancer in individuals with previous colorectal neoplasia: systematic review and network meta-analysis.

Authors:  Parambir S Dulai; Siddharth Singh; Evelyn Marquez; Rohan Khera; Larry J Prokop; Paul J Limburg; Samir Gupta; Mohammad Hassan Murad
Journal:  BMJ       Date:  2016-12-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.